Bavarian Nordic sells discount shares to help fund Covid-19 vaccine

Bavarian Nordic has completed a new round of selling equity and has raised USD 175.8m in gross proceeds, which will in part help finance the firm's Covid-19 vaccine and ease the way to new acquisitions.

Photo: Bavarian Nordic / PR

Bavarian Nordic has sold shares worth DKK 1.1bn (USD 175.8m) at DKK 223 per share, which will partly go towards financing the company's further development of the Covid-19 vaccine which the firm has in-licensed from Adaptvac.

Thus, the share prices had a 5.3-percent discount compared with Tuesday's closing price at DKK 235.60.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs